Goodwin Procter advised the underwriters on the deal. Genenta Science S.p.A.’s (Nasdaq: GNTA) announced its upsized initial public offering, making history as the first Italian biotech to...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised AbCellera on the deal. AbCellera (Nasdaq: ABCL) announced its acquisition of TetraGenetics. AbCellera is a technology company with a centralized operating system for next-generation...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Absci, while Latham & Watkins represented the underwriters in the offering. Absci Corporation (Absci), the synthetic biology company unlocking the potential of proteins...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised the underwriters, while Latham & Watkins represented Rapid Micro Biosystems, Inc. in the offering. Rapid Micro Biosystems, Inc. (Nasdaq: RPID), an innovative life sciences...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Intellia Therapeutics on the deal. Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced its $690 million underwritten public offering on the heels of releasing the first-ever...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP and JunHe advised Goldman Sachs & Co. LLC and the other underwriters on the deal, while Wilson Sonsini Goodrich & Rosati and Maples...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised COMPASS Pathways plc on the deal. COMPASS Pathways plc (Nasdaq: CMPS) announced its public follow-on offering of 4,000,000 American Depositary Shares (“ADSs”) representing...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised COMPASS Pathways plc on the deal. COMPASS Pathways plc (Nasdaq: CMPS) announced its public follow-on offering of 4,000,000 American Depositary Shares (“ADSs”) representing...
You must be a Standard 1 Year member to access this content.
